vs
Side-by-side financial comparison of F5, Inc. (FFIV) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
F5, Inc. is the larger business by last-quarter revenue ($822.5M vs $708.5M, roughly 1.2× Medpace Holdings, Inc.). F5, Inc. runs the higher net margin — 21.9% vs 19.1%, a 2.8% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 7.3%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $149.5M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 9.9%).
F5, Inc. is an American technology company specializing in application security, multi-cloud management, online fraud prevention, application delivery networking (ADN), application availability and performance, and network security, access, and authorization.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
FFIV vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $822.5M | $708.5M |
| Net Profit | $180.1M | $135.1M |
| Gross Margin | 81.5% | — |
| Operating Margin | 26.0% | 21.6% |
| Net Margin | 21.9% | 19.1% |
| Revenue YoY | 7.3% | 32.0% |
| Net Profit YoY | 8.2% | 15.5% |
| EPS (diluted) | $3.10 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $822.5M | $708.5M | ||
| Q3 25 | $810.1M | $659.9M | ||
| Q2 25 | $780.4M | $603.3M | ||
| Q1 25 | $731.1M | $558.6M | ||
| Q4 24 | $766.5M | $536.6M | ||
| Q3 24 | $746.7M | $533.3M | ||
| Q2 24 | $695.5M | $528.1M | ||
| Q1 24 | $681.4M | $511.0M |
| Q4 25 | $180.1M | $135.1M | ||
| Q3 25 | $190.5M | $111.1M | ||
| Q2 25 | $189.9M | $90.3M | ||
| Q1 25 | $145.5M | $114.6M | ||
| Q4 24 | $166.4M | $117.0M | ||
| Q3 24 | $165.3M | $96.4M | ||
| Q2 24 | $144.1M | $88.4M | ||
| Q1 24 | $119.0M | $102.6M |
| Q4 25 | 81.5% | — | ||
| Q3 25 | 82.2% | — | ||
| Q2 25 | 81.0% | — | ||
| Q1 25 | 80.7% | — | ||
| Q4 24 | 81.7% | — | ||
| Q3 24 | 80.8% | — | ||
| Q2 24 | 80.4% | — | ||
| Q1 24 | 79.3% | — |
| Q4 25 | 26.0% | 21.6% | ||
| Q3 25 | 25.4% | 21.5% | ||
| Q2 25 | 25.2% | 20.9% | ||
| Q1 25 | 21.7% | 20.3% | ||
| Q4 24 | 26.8% | 23.4% | ||
| Q3 24 | 25.6% | 21.1% | ||
| Q2 24 | 23.4% | 19.9% | ||
| Q1 24 | 20.5% | 20.4% |
| Q4 25 | 21.9% | 19.1% | ||
| Q3 25 | 23.5% | 16.8% | ||
| Q2 25 | 24.3% | 15.0% | ||
| Q1 25 | 19.9% | 20.5% | ||
| Q4 24 | 21.7% | 21.8% | ||
| Q3 24 | 22.1% | 18.1% | ||
| Q2 24 | 20.7% | 16.7% | ||
| Q1 24 | 17.5% | 20.1% |
| Q4 25 | $3.10 | $4.65 | ||
| Q3 25 | $3.25 | $3.86 | ||
| Q2 25 | $3.25 | $3.10 | ||
| Q1 25 | $2.48 | $3.67 | ||
| Q4 24 | $2.82 | $3.67 | ||
| Q3 24 | $2.79 | $3.01 | ||
| Q2 24 | $2.44 | $2.75 | ||
| Q1 24 | $2.00 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.5B | $459.1M |
| Total Assets | $6.3B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | $497.0M | ||
| Q3 25 | $1.3B | $285.4M | ||
| Q2 25 | $1.4B | $46.3M | ||
| Q1 25 | $1.3B | $441.4M | ||
| Q4 24 | $1.2B | $669.4M | ||
| Q3 24 | $1.1B | $656.9M | ||
| Q2 24 | $935.6M | $510.9M | ||
| Q1 24 | $903.5M | $407.0M |
| Q4 25 | $3.5B | $459.1M | ||
| Q3 25 | $3.6B | $293.6M | ||
| Q2 25 | $3.5B | $172.4M | ||
| Q1 25 | $3.3B | $593.6M | ||
| Q4 24 | $3.2B | $825.5M | ||
| Q3 24 | $3.1B | $881.4M | ||
| Q2 24 | $3.0B | $763.6M | ||
| Q1 24 | $2.9B | $671.5M |
| Q4 25 | $6.3B | $2.0B | ||
| Q3 25 | $6.3B | $1.8B | ||
| Q2 25 | $6.1B | $1.6B | ||
| Q1 25 | $5.9B | $1.9B | ||
| Q4 24 | $5.9B | $2.1B | ||
| Q3 24 | $5.6B | $2.1B | ||
| Q2 24 | $5.4B | $1.9B | ||
| Q1 24 | $5.4B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $159.2M | $192.7M |
| Free Cash FlowOCF − Capex | $149.5M | $188.1M |
| FCF MarginFCF / Revenue | 18.2% | 26.6% |
| Capex IntensityCapex / Revenue | 1.2% | 0.6% |
| Cash ConversionOCF / Net Profit | 0.88× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $861.2M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $159.2M | $192.7M | ||
| Q3 25 | $208.1M | $246.2M | ||
| Q2 25 | $282.2M | $148.5M | ||
| Q1 25 | $256.6M | $125.8M | ||
| Q4 24 | $202.8M | $190.7M | ||
| Q3 24 | $246.5M | $149.1M | ||
| Q2 24 | $159.0M | $116.4M | ||
| Q1 24 | $221.6M | $152.7M |
| Q4 25 | $149.5M | $188.1M | ||
| Q3 25 | $191.9M | $235.5M | ||
| Q2 25 | $273.7M | $142.4M | ||
| Q1 25 | $246.1M | $115.8M | ||
| Q4 24 | $194.7M | $183.0M | ||
| Q3 24 | $240.4M | $138.5M | ||
| Q2 24 | $153.1M | $103.5M | ||
| Q1 24 | $212.2M | $147.2M |
| Q4 25 | 18.2% | 26.6% | ||
| Q3 25 | 23.7% | 35.7% | ||
| Q2 25 | 35.1% | 23.6% | ||
| Q1 25 | 33.7% | 20.7% | ||
| Q4 24 | 25.4% | 34.1% | ||
| Q3 24 | 32.2% | 26.0% | ||
| Q2 24 | 22.0% | 19.6% | ||
| Q1 24 | 31.1% | 28.8% |
| Q4 25 | 1.2% | 0.6% | ||
| Q3 25 | 2.0% | 1.6% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 1.4% | 1.8% | ||
| Q4 24 | 1.1% | 1.4% | ||
| Q3 24 | 0.8% | 2.0% | ||
| Q2 24 | 0.8% | 2.4% | ||
| Q1 24 | 1.4% | 1.1% |
| Q4 25 | 0.88× | 1.43× | ||
| Q3 25 | 1.09× | 2.22× | ||
| Q2 25 | 1.49× | 1.65× | ||
| Q1 25 | 1.76× | 1.10× | ||
| Q4 24 | 1.22× | 1.63× | ||
| Q3 24 | 1.49× | 1.55× | ||
| Q2 24 | 1.10× | 1.32× | ||
| Q1 24 | 1.86× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FFIV
| Services | $412.2M | 50% |
| Products | $410.3M | 50% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
